Exchange: NASDAQ Sector: Healthcare Industry: Diagnostics & Research
Current Signal: BUY (auto-tracking)
3.26% $69.06
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 12 537 mill |
EPS: | -1.130 |
P/E: | -61.12 |
Earnings Date: | May 07, 2024 |
SharesOutstanding: | 181.53 mill |
Avg Daily Volume: | 1.958 mill |
RATING 2024-03-28 |
---|
A |
Buy |
RATINGS | ||
---|---|---|
Rating CashFlow: | Buy | |
Return On Equity: | Neutral | |
Return On Asset: | Buy | |
DE: | Strong Buy | |
P/E: | Strong Sell | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -61.12 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-3.27x |
Company: PE -61.12 | industry: PE 18.71 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 66.24 - 71.89 ( +/- 4.09%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-29 | Orville Jacob A | Buy | 4 724 | Common Stock |
2024-03-01 | Orville Jacob A | Sell | 2 154 | Common Stock |
2024-02-29 | Orville Jacob A | Sell | 4 724 | Restricted Stock Units |
2024-03-01 | Levangie Daniel J | Sell | 5 000 | Common Stock |
2024-02-29 | Herriott James | Buy | 1 890 | Common Stock |
INSIDER POWER |
---|
37.39 |
Last 100 transactions |
Buy: 546 749 | Sell: 248 946 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $69.06 (3.26% ) |
Volume | 5.38 mill |
Avg. Vol. | 1.958 mill |
% of Avg. Vol | 274.93 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $60.93 | N/A | Active |
---|
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.